Cargando…

Diagnostic model development for schizophrenia based on peripheral blood mononuclear cell subtype-specific expression of metabolic markers

A significant proportion of the personal and economic burden of schizophrenia can be attributed to the late diagnosis or misdiagnosis of the disorder. A novel, objective diagnostic approaches could facilitate the early detection and treatment of schizophrenia and improve patient outcomes. In the pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaki, Jihan K., Lago, Santiago G., Rustogi, Nitin, Gangadin, Shiral S., Benacek, Jiri, van Rees, Geertje F., Haenisch, Frieder, Broek, Jantine A., Suarez-Pinilla, Paula, Ruland, Tillmann, Auyeung, Bonnie, Mikova, Olya, Kabacs, Nikolett, Arolt, Volker, Baron-Cohen, Simon, Crespo-Facorro, Benedicto, Drexhage, Hemmo A., de Witte, Lot D., Kahn, René S., Sommer, Iris E., Bahn, Sabine, Tomasik, Jakub
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618570/
https://www.ncbi.nlm.nih.gov/pubmed/36310155
http://dx.doi.org/10.1038/s41398-022-02229-w
_version_ 1784821078513680384
author Zaki, Jihan K.
Lago, Santiago G.
Rustogi, Nitin
Gangadin, Shiral S.
Benacek, Jiri
van Rees, Geertje F.
Haenisch, Frieder
Broek, Jantine A.
Suarez-Pinilla, Paula
Ruland, Tillmann
Auyeung, Bonnie
Mikova, Olya
Kabacs, Nikolett
Arolt, Volker
Baron-Cohen, Simon
Crespo-Facorro, Benedicto
Drexhage, Hemmo A.
de Witte, Lot D.
Kahn, René S.
Sommer, Iris E.
Bahn, Sabine
Tomasik, Jakub
author_facet Zaki, Jihan K.
Lago, Santiago G.
Rustogi, Nitin
Gangadin, Shiral S.
Benacek, Jiri
van Rees, Geertje F.
Haenisch, Frieder
Broek, Jantine A.
Suarez-Pinilla, Paula
Ruland, Tillmann
Auyeung, Bonnie
Mikova, Olya
Kabacs, Nikolett
Arolt, Volker
Baron-Cohen, Simon
Crespo-Facorro, Benedicto
Drexhage, Hemmo A.
de Witte, Lot D.
Kahn, René S.
Sommer, Iris E.
Bahn, Sabine
Tomasik, Jakub
author_sort Zaki, Jihan K.
collection PubMed
description A significant proportion of the personal and economic burden of schizophrenia can be attributed to the late diagnosis or misdiagnosis of the disorder. A novel, objective diagnostic approaches could facilitate the early detection and treatment of schizophrenia and improve patient outcomes. In the present study, we aimed to identify robust schizophrenia-specific blood biomarkers, with the goal of developing an accurate diagnostic model. The levels of selected serum and peripheral blood mononuclear cell (PBMC) markers relevant to metabolic and immune function were measured in healthy controls (n = 26) and recent-onset schizophrenia patients (n = 36) using multiplexed immunoassays and flow cytometry. Analysis of covariance revealed significant upregulation of insulin receptor (IR) and fatty acid translocase (CD36) levels in T helper cells (F = 10.75, P = 0.002, Q = 0.024 and F = 21.58, P = 2.8 × 10(−5), Q = 0.0004, respectively), as well as downregulation of glucose transporter 1 (GLUT1) expression in monocytes (F = 21.46, P = 2.9 × 10(−5), Q = 0.0004). The most robust predictors, monocyte GLUT1 and T helper cell CD36, were used to develop a diagnostic model, which showed a leave-one-out cross-validated area under the receiver operating characteristic curve (AUC) of 0.78 (95% CI: 0.66–0.92). The diagnostic model was validated in two independent datasets. The model was able to distinguish first-onset, drug-naïve schizophrenia patients (n = 34) from healthy controls (n = 39) with an AUC of 0.75 (95% CI: 0.64–0.86), and also differentiated schizophrenia patients (n = 22) from patients with other neuropsychiatric conditions, including bipolar disorder, major depressive disorder and autism spectrum disorder (n = 68), with an AUC of 0.83 (95% CI: 0.75–0.92). These findings indicate that PBMC-derived biomarkers have the potential to support an accurate and objective differential diagnosis of schizophrenia.
format Online
Article
Text
id pubmed-9618570
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-96185702022-11-01 Diagnostic model development for schizophrenia based on peripheral blood mononuclear cell subtype-specific expression of metabolic markers Zaki, Jihan K. Lago, Santiago G. Rustogi, Nitin Gangadin, Shiral S. Benacek, Jiri van Rees, Geertje F. Haenisch, Frieder Broek, Jantine A. Suarez-Pinilla, Paula Ruland, Tillmann Auyeung, Bonnie Mikova, Olya Kabacs, Nikolett Arolt, Volker Baron-Cohen, Simon Crespo-Facorro, Benedicto Drexhage, Hemmo A. de Witte, Lot D. Kahn, René S. Sommer, Iris E. Bahn, Sabine Tomasik, Jakub Transl Psychiatry Article A significant proportion of the personal and economic burden of schizophrenia can be attributed to the late diagnosis or misdiagnosis of the disorder. A novel, objective diagnostic approaches could facilitate the early detection and treatment of schizophrenia and improve patient outcomes. In the present study, we aimed to identify robust schizophrenia-specific blood biomarkers, with the goal of developing an accurate diagnostic model. The levels of selected serum and peripheral blood mononuclear cell (PBMC) markers relevant to metabolic and immune function were measured in healthy controls (n = 26) and recent-onset schizophrenia patients (n = 36) using multiplexed immunoassays and flow cytometry. Analysis of covariance revealed significant upregulation of insulin receptor (IR) and fatty acid translocase (CD36) levels in T helper cells (F = 10.75, P = 0.002, Q = 0.024 and F = 21.58, P = 2.8 × 10(−5), Q = 0.0004, respectively), as well as downregulation of glucose transporter 1 (GLUT1) expression in monocytes (F = 21.46, P = 2.9 × 10(−5), Q = 0.0004). The most robust predictors, monocyte GLUT1 and T helper cell CD36, were used to develop a diagnostic model, which showed a leave-one-out cross-validated area under the receiver operating characteristic curve (AUC) of 0.78 (95% CI: 0.66–0.92). The diagnostic model was validated in two independent datasets. The model was able to distinguish first-onset, drug-naïve schizophrenia patients (n = 34) from healthy controls (n = 39) with an AUC of 0.75 (95% CI: 0.64–0.86), and also differentiated schizophrenia patients (n = 22) from patients with other neuropsychiatric conditions, including bipolar disorder, major depressive disorder and autism spectrum disorder (n = 68), with an AUC of 0.83 (95% CI: 0.75–0.92). These findings indicate that PBMC-derived biomarkers have the potential to support an accurate and objective differential diagnosis of schizophrenia. Nature Publishing Group UK 2022-10-30 /pmc/articles/PMC9618570/ /pubmed/36310155 http://dx.doi.org/10.1038/s41398-022-02229-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zaki, Jihan K.
Lago, Santiago G.
Rustogi, Nitin
Gangadin, Shiral S.
Benacek, Jiri
van Rees, Geertje F.
Haenisch, Frieder
Broek, Jantine A.
Suarez-Pinilla, Paula
Ruland, Tillmann
Auyeung, Bonnie
Mikova, Olya
Kabacs, Nikolett
Arolt, Volker
Baron-Cohen, Simon
Crespo-Facorro, Benedicto
Drexhage, Hemmo A.
de Witte, Lot D.
Kahn, René S.
Sommer, Iris E.
Bahn, Sabine
Tomasik, Jakub
Diagnostic model development for schizophrenia based on peripheral blood mononuclear cell subtype-specific expression of metabolic markers
title Diagnostic model development for schizophrenia based on peripheral blood mononuclear cell subtype-specific expression of metabolic markers
title_full Diagnostic model development for schizophrenia based on peripheral blood mononuclear cell subtype-specific expression of metabolic markers
title_fullStr Diagnostic model development for schizophrenia based on peripheral blood mononuclear cell subtype-specific expression of metabolic markers
title_full_unstemmed Diagnostic model development for schizophrenia based on peripheral blood mononuclear cell subtype-specific expression of metabolic markers
title_short Diagnostic model development for schizophrenia based on peripheral blood mononuclear cell subtype-specific expression of metabolic markers
title_sort diagnostic model development for schizophrenia based on peripheral blood mononuclear cell subtype-specific expression of metabolic markers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618570/
https://www.ncbi.nlm.nih.gov/pubmed/36310155
http://dx.doi.org/10.1038/s41398-022-02229-w
work_keys_str_mv AT zakijihank diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT lagosantiagog diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT rustoginitin diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT gangadinshirals diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT benacekjiri diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT vanreesgeertjef diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT haenischfrieder diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT broekjantinea diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT suarezpinillapaula diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT rulandtillmann diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT auyeungbonnie diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT mikovaolya diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT kabacsnikolett diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT aroltvolker diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT baroncohensimon diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT crespofacorrobenedicto diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT drexhagehemmoa diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT dewittelotd diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT kahnrenes diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT sommeririse diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT bahnsabine diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers
AT tomasikjakub diagnosticmodeldevelopmentforschizophreniabasedonperipheralbloodmononuclearcellsubtypespecificexpressionofmetabolicmarkers